CA2901613C - Dual mek/pi3k inhibitors and therapeutic methods using the same - Google Patents
Dual mek/pi3k inhibitors and therapeutic methods using the same Download PDFInfo
- Publication number
- CA2901613C CA2901613C CA2901613A CA2901613A CA2901613C CA 2901613 C CA2901613 C CA 2901613C CA 2901613 A CA2901613 A CA 2901613A CA 2901613 A CA2901613 A CA 2901613A CA 2901613 C CA2901613 C CA 2901613C
- Authority
- CA
- Canada
- Prior art keywords
- mek
- pi3k
- compound
- structural formula
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779462P | 2013-03-13 | 2013-03-13 | |
| US61/779,462 | 2013-03-13 | ||
| PCT/US2014/023860 WO2014164942A1 (en) | 2013-03-13 | 2014-03-12 | Dual mek/pi3k inhibitors and therapeutic methods using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2901613A1 CA2901613A1 (en) | 2014-10-09 |
| CA2901613C true CA2901613C (en) | 2020-10-20 |
Family
ID=51659015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2901613A Active CA2901613C (en) | 2013-03-13 | 2014-03-12 | Dual mek/pi3k inhibitors and therapeutic methods using the same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9611258B2 (OSRAM) |
| EP (1) | EP2968345B1 (OSRAM) |
| JP (1) | JP6315848B2 (OSRAM) |
| CN (1) | CN105358156A (OSRAM) |
| CA (1) | CA2901613C (OSRAM) |
| WO (1) | WO2014164942A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016001485A1 (en) | 2014-06-30 | 2016-01-07 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| US9968604B2 (en) * | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| CA3004530A1 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| CA3029875C (en) * | 2016-07-06 | 2023-12-19 | The Regents Of The University Of Michigan | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| JP7350336B2 (ja) * | 2017-08-11 | 2023-09-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | ＭＥＫ／ＰＩ３Ｋ、ＪＡＫ／ＭＥＫ、ＪＡＫ／ＰＩ３Ｋ／ｍＴＯＲおよびＭＥＫ／ＰＩ３Ｋ／ｍＴＯＲの生物学的経路の阻害剤、および治療化合物のリンパ取り込み、生物学的利用能、および溶解性を改善する方法 |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CA3166636A1 (en) * | 2020-01-10 | 2021-07-15 | Immuneering Corporation | Mek inhibitors and therapeutic uses thereof |
| CN111135309B (zh) * | 2020-01-15 | 2023-04-28 | 重庆大学 | 一种核壳结构的替拉扎明药物载体及其制备方法和应用 |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| CA3245088A1 (en) * | 2022-01-06 | 2023-07-13 | Immuneering Corporation | MEK IMMUNE ONCOLOGICAL INHIBITORS AND THEIR THERAPEUTIC USES |
| WO2024102859A1 (en) * | 2022-11-09 | 2024-05-16 | Immuneering Corporation | Mek immune oncology inhibitors and therapeutic uses thereof |
| WO2025010287A2 (en) * | 2023-07-03 | 2025-01-09 | Immuneering Corporation | Mek immune oncology inhibitors and therapeutic uses thereof |
| WO2025114495A1 (en) * | 2023-11-28 | 2025-06-05 | Universität Basel | Pi3k inhibitors and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960614B2 (en) * | 2000-07-19 | 2005-11-01 | Warner-Lambert Company | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| WO2008032060A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032033A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| US8569378B2 (en) * | 2007-07-20 | 2013-10-29 | Toshiyuki Sakai | p27 protein inducer |
| JP2011515462A (ja) * | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
| JP2011527703A (ja) * | 2008-07-11 | 2011-11-04 | ノバルティス アーゲー | （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物 |
| JP5766177B2 (ja) | 2009-03-27 | 2015-08-19 | ベトディーシー，インコーポレイテッド | ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用 |
| CA2987503C (en) | 2009-07-07 | 2019-02-26 | Mei Pharma, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| US20110166191A1 (en) * | 2010-01-07 | 2011-07-07 | Shijun Zhang | 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer |
| GB201007227D0 (en) * | 2010-04-30 | 2010-06-16 | Univ Basel | Piperazinotriazines |
| EP3693017A1 (en) * | 2010-12-14 | 2020-08-12 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
-
2014
- 2014-03-12 CA CA2901613A patent/CA2901613C/en active Active
- 2014-03-12 US US14/771,233 patent/US9611258B2/en active Active
- 2014-03-12 WO PCT/US2014/023860 patent/WO2014164942A1/en not_active Ceased
- 2014-03-12 EP EP14779150.3A patent/EP2968345B1/en active Active
- 2014-03-12 CN CN201480014555.XA patent/CN105358156A/zh active Pending
- 2014-03-12 JP JP2016501365A patent/JP6315848B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014164942A1 (en) | 2014-10-09 |
| JP2016516702A (ja) | 2016-06-09 |
| EP2968345A1 (en) | 2016-01-20 |
| US20160002212A1 (en) | 2016-01-07 |
| CN105358156A (zh) | 2016-02-24 |
| US9611258B2 (en) | 2017-04-04 |
| CA2901613A1 (en) | 2014-10-09 |
| EP2968345B1 (en) | 2017-12-13 |
| EP2968345A4 (en) | 2016-08-17 |
| JP6315848B2 (ja) | 2018-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2901613C (en) | Dual mek/pi3k inhibitors and therapeutic methods using the same | |
| AU2021202619B2 (en) | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | |
| EP2888265B1 (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same | |
| US20110319362A1 (en) | Stat3 ligands and therapeutic uses thereof | |
| WO2011159685A2 (en) | Inhibition of wdr5 interaction with its binding partners and therapeutic methods | |
| CA2825306A1 (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same | |
| EP4460306A2 (en) | Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4) | |
| WO2013082017A1 (en) | Cyclized peptidomimetic small molecule inhibitors of the wdr5 and mll1 interaction | |
| AU2018316175B2 (en) | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | |
| EP4168003A2 (en) | Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181017 |